• SCORAD Score change taken at baseline and after 1 month of either probiotic or placebo
  
• T Regulatory cell activity change taken at baseline and after 1 month of either probiotic or placebo
  

• Dermatitis Family Impact Questionnaire change taken at baseline and after 1 month of either probiotic or placebo
  
• T Regulatory cell activity when exposed to probiotics in vitro
  
• Change in Serum IgE or IgG levels taken at baseline and after 1 month of either probiotic or placebo
  

The central hypothesis of this study is that a subset of commercially available probiotic formulations will ameliorate moderate to severe atopic dermatitis in children by inducing the development of T Regulatory (Treg) cells. We specifically hypothesize that the probiotic mixture that induces Treg activity in vitro, will also improve the severity of atopic dermatitis in a specific patient by inducing Treg activity in vivo.

1. We will determine whether probiotic mixtures are better able to ameliorate the severity of atopic dermatitis when compared to patients treated with placebo. We will conduct a 4-week randomized, double-blind, placebo controlled clinical trial designed to evaluate the efficacy of probiotics in reducing the clinical severity of atopic dermatitis as assessed by our primary outcome measure, the SCORing Atopic Dermatitis (SCORAD) index. We specifically hypothesize that probiotics will clinically improve the disease.
2. We will assess whether probiotic mixtures induce the development of T regulatory cells in patients with atopic dermatitis.

A. We will measure the relative levels of Tregs in peripheral blood before and after probiotic or placebo administration in order to assess whether the probiotic mixtures alter Treg development in vivo, and whether these changes correlate with improvement in clinical scores. Primary outcomes will be measurements of gene expression and absolute increases in cell population. We specifically hypothesize that probiotics will increase Treg activity.

B. We will also determine if all patients' Tregs have in vitro responses to probiotics. This data will be used to correlate whether clinical responders in the study also have strong in vitro responses.

Inclusion Criteria:

• Age between 6 months to 3 years
• Physician diagnosis of moderate to severe atopic dermatitis as defined by the Hanifin and Rajka criteria
• Ability to take enterally commercially available probiotics by powder form added to food or drink
• Ability to undergo venipuncture or dermal puncture (if less than 1 year old)

Exclusion Criteria:

• Prior exposure to probiotics
• Current antibiotic administration
• Known history of chronic medical condition such as congenital heart disease, liver or kidney disease, or immune deficiency
• Absence of T regulatory cell induction by probiotic bacteria on initial laboratory assessment
• Any other condition in which the Investigators involved in the study determine potential subject is unsuitable for the study